• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by NextCure Inc.

    12/9/25 9:32:37 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NXTC alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001.

    FORM D

    Notice of Exempt Offering of Securities
    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
    X None
    Entity Type
    0001661059
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    NextCure, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    NextCure, Inc.
    Street Address 1 Street Address 2
    9000 VIRGINIA MANOR ROAD SUITE 200
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    BELTSVILLE MARYLAND 20705 240-399-4900

    3. Related Persons

    Last Name First Name Middle Name
    Richman Michael
    Street Address 1 Street Address 2
    9000 Virginia Manor Road Suite 200
    City State/Province/Country ZIP/PostalCode
    Beltsville MARYLAND 20705
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cobourn Steven P.
    Street Address 1 Street Address 2
    9000 Virginia Manor Road Suite 200
    City State/Province/Country ZIP/PostalCode
    Beltsville MARYLAND 20705
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kabakoff David
    Street Address 1 Street Address 2
    9000 Virginia Manor Road Suite 200
    City State/Province/Country ZIP/PostalCode
    Beltsville MARYLAND 20705
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Jones Elaine V.
    Street Address 1 Street Address 2
    9000 Virginia Manor Road Suite 200
    City State/Province/Country ZIP/PostalCode
    Beltsville MARYLAND 20705
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Houston John G.
    Street Address 1 Street Address 2
    9000 Virginia Manor Road Suite 200
    City State/Province/Country ZIP/PostalCode
    Beltsville MARYLAND 20705
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Webster Stephen
    Street Address 1 Street Address 2
    9000 Virginia Manor Road Suite 200
    City State/Province/Country ZIP/PostalCode
    Beltsville MARYLAND 20705
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Feigal Ellen G.
    Street Address 1 Street Address 2
    9000 Virginia Manor Road Suite 200
    City State/Province/Country ZIP/PostalCode
    Beltsville MARYLAND 20705
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Borgman Anne
    Street Address 1 Street Address 2
    9000 Virginia Manor Road Suite 200
    City State/Province/Country ZIP/PostalCode
    Beltsville MARYLAND 20705
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Guha Udayan
    Street Address 1 Street Address 2
    9000 Virginia Manor Road Suite 200
    City State/Province/Country ZIP/PostalCode
    Beltsville MARYLAND 20705
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Mayer Timothy
    Street Address 1 Street Address 2
    9000 Virginia Manor Road Suite 200
    City State/Province/Country ZIP/PostalCode
    Beltsville MARYLAND 20705
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kundu Sourav
    Street Address 1 Street Address 2
    9000 Virginia Manor Road Suite 200
    City State/Province/Country ZIP/PostalCode
    Beltsville MARYLAND 20705
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Shaw Kevin
    Street Address 1 Street Address 2
    9000 Virginia Manor Road Suite 200
    City State/Province/Country ZIP/PostalCode
    Beltsville MARYLAND 20705
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
    X No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
       Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-11-12    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    H.C. Wainwright & Co., LLC 000000375
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    430 Park Avenue 4th Floor
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10022
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    ILLINOIS
    MASSACHUSETTS
    NEW YORK
    TEXAS

    13. Offering and Sales Amounts

    Total Offering Amount $21,500,000 USD
    or    Indefinite
    Total Amount Sold $21,500,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    12

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $1,215,001 USD
       Estimate

    Clarification of Response (if Necessary):

    The placement agent received at closing a cash fee equal to a percentage of the aggregate consideration plus certain expenses.

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    NextCure, Inc. /s/ Michael Richman Michael Richman President and CEO 2025-12-09

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $NXTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXTC

    DatePrice TargetRatingAnalyst
    11/7/2025$18.00Neutral → Buy
    Ladenburg Thalmann
    11/4/2022Buy → Neutral
    Ladenburg Thalmann
    3/1/2022$16.00Buy
    Ladenburg Thalmann
    11/5/2021$30.00 → $14.00Buy
    Needham
    More analyst ratings

    $NXTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

    BELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City on Wednesday, December 3rd, at 11:00 am ET. A live audio webcast will be available through the Investors section of the company's website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days. About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company

    11/20/25 8:00:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

    Extends cash runway into first half of 2027, beyond planned first half of 2026 proof of concept ("POC") data readouts of SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC)Led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, and Exome Asset Management in a private placement of common stock priced at the market BELTSVILLE, Md., Nov. 17, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced the closing of its previously announced private placement in public equity ("PIPE"). The PIPE was led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare F

    11/17/25 8:00:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

    BELTSVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced that it has entered into definitive agreements with the participation of certain institutional and accredited investors, including Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, LP., Exome Asset Management as well as other healthcare focused funds, for the purchase and sale of an aggregate of 2,523,477 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $8.52 per share of common stock (or pre-funded warrant in lieu thereof) in a private

    11/12/25 8:00:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: New insider Simcere Zaiming, Inc. claimed ownership of 338,636 shares (SEC Form 3)

    3/A - NextCure, Inc. (0001661059) (Issuer)

    9/29/25 4:00:11 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Simcere Zaiming, Inc. claimed ownership of 338,636 shares (SEC Form 3)

    3 - NextCure, Inc. (0001661059) (Issuer)

    8/19/25 9:32:24 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Houston John G

    4 - NextCure, Inc. (0001661059) (Issuer)

    6/24/25 4:31:30 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    SEC Filings

    View All

    SEC Form EFFECT filed by NextCure Inc.

    EFFECT - NextCure, Inc. (0001661059) (Filer)

    12/12/25 12:15:37 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B1 filed by NextCure Inc.

    424B1 - NextCure, Inc. (0001661059) (Filer)

    12/11/25 4:59:24 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by NextCure Inc.

    D - NextCure, Inc. (0001661059) (Filer)

    12/9/25 9:32:37 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NextCure upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded NextCure from Neutral to Buy and set a new price target of $18.00

    11/7/25 8:06:56 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded NextCure from Buy to Neutral

    11/4/22 1:03:13 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on NextCure with a new price target

    Ladenburg Thalmann initiated coverage of NextCure with a rating of Buy and set a new price target of $16.00

    3/1/22 7:18:07 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Leadership Updates

    Live Leadership Updates

    View All

    NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

    BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4. "We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug c

    4/4/24 7:05:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

    BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board. As an accomplished translational tumor immunologist whose research is focused on the role immune cells play in tumor development, Dr. Coussens will support NextCure in its efforts to build and develop its proprietary pipeline of immunomedicines. "We are delighted to have Dr. Coussens join our Scientific Advisory Board, where she will leverage

    10/27/22 4:05:00 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

    BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 financial results and provided a business update. “Our team has worked diligently throughout 2020 to advance our programs despite the difficult environment created by the COVID-19 pandemic. We are thrilled that Dr. Han Myint has recently joined NextCure as our Chief Medical Officer and we are poised to harness his expertise in oncology product development to further advance our product pipe

    3/4/21 4:05:00 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Financials

    Live finance-specific insights

    View All

    NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021

    BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will host a Virtual Oncology Pipeline Update Event at 4:30 p.m. ET on Monday, November 15, 2021. During the event, NextCure will provide an update on its oncology pipeline, including data presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting. The event will also feature Roy Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Directo

    11/1/21 8:00:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NextCure Inc.

    SC 13G/A - NextCure, Inc. (0001661059) (Subject)

    11/14/24 6:59:21 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NextCure Inc.

    SC 13G/A - NextCure, Inc. (0001661059) (Subject)

    11/13/24 4:06:36 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by NextCure Inc.

    SC 13G - NextCure, Inc. (0001661059) (Subject)

    6/27/24 4:47:26 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care